近年来，医保目录在调整中始终以人民群众的健康为核心，建立全面支持创新药以造福患者的准入机 制，助力构建覆盖14亿人的全国统一大市场，建立健全药品创新价值评估机制，在支持创新药发展方面 发挥了重要作用。有理由相信，以优化创新药支持政策与构建创新药多元支付体系为重心，充分激发医 药产业创新活力，将有效提升创新药研发积极性与患者可及性，更好保障人民群众生命健康，构建更具 竞争力、更有持续性的医药产业新生态。 12月7日，备受社会关注的2025年国家医保药品目录及首版商保创新药目录发布。2025年国家医保药品 目录成功新增114种药品，有50种是1类创新药，总体成功率88%，较2024年的76%明显提高。同时19种 药品纳入首版商保创新药目录。专家指出，支持创新药进入基本医保目录和商保创新药目录、支持创新 药临床应用、提高创新药多元支付能力和强化保障措施等维度的配套政策体系，为创新药品从实验室研 发到临床支付的全链条打通了"最后一公里"。 随着国产创新药多元支持体系的进一步完善，诸多创新药得以加速问世，为患者带来生的希望。药品谈 判将不少创新药纳入报销目录，极大减轻了患者的经济负担。近年来，医保目录在调整中始终以人民 ...

Core Viewpoint - The company reported steady revenue growth and exceeded profit expectations in Q3 2025, driven by a low base from the previous year and a higher number of project settlements [1][2][3]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 607 million, a year-on-year increase of 8.09%, and a net profit attributable to shareholders of 96 million, up 13.21%. The net profit after deducting non-recurring items was 81 million, reflecting a growth of 22.47% [1]. - In Q3 2025 alone, the company recorded revenue of 228 million, representing a year-on-year growth of 24.48%. The net profit attributable to shareholders was 34 million, up 32.98%, while the net profit after deducting non-recurring items reached 30 million, marking a significant increase of 52.69% [2]. - The gross profit margin for the first three quarters was 35.61%, down 3.58 percentage points year-on-year, while the net profit margin increased by 0.65 percentage points to 15.94%. Management and sales expense ratios improved, with management expenses at 10.07% (down 5.11 percentage points) and sales expenses at 1.66% (down 0.24 percentage points) [2]. Industry Outlook - The onset of a rate-cutting cycle by the Federal Reserve, with a 25 basis point cut in September 2025 and expectations for further cuts, is anticipated to gradually revive investment and financing, benefiting the clinical CRO sector [3]. - The introduction of domestic innovative drug support policies is expected to favor local clinical CROs, positioning the company for rapid growth opportunities [3]. Profit Forecast and Investment Recommendation - Revenue projections for 2025-2027 are estimated at 776 million, 852 million, and 969 million, with year-on-year growth rates of 4.33%, 9.75%, and 13.79%, respectively. Net profit attributable to shareholders is forecasted at 150 million, 163 million, and 181 million, with growth rates of 6.85%, 8.83%, and 11.26% [3]. - The company is assigned a "buy" rating with corresponding price-to-earnings ratios of 33, 31, and 28 for the years 2025, 2026, and 2027 [3].

Summary of Key Points from the Conference Call on the Pharmaceutical Industry Industry Overview - The conference call discusses the pharmaceutical industry, particularly focusing on the impact of recent government policies regarding centralized procurement and price control measures [1][2]. Core Insights and Arguments 1. **Government Regulation and Price Control**: The National Development and Reform Commission (NDRC) and the State Administration for Market Regulation are intensifying controls on price wars across various industries, including pharmaceuticals, to combat deflation [1][2]. 2. **Impact of Medical Insurance Reform**: Medical insurance reforms have led to lower drug and consumable prices but have also caused issues such as production halts, quality declines, and reduced investment in innovative drug development [1][4]. 3. **Centralized Procurement Effects**: Centralized procurement has significantly reduced drug prices, with over 70% of drugs used in public hospitals procured through this method. However, this has resulted in production stoppages and quality issues for some companies [3][4]. 4. **Support for Innovative Drugs**: The government is implementing measures to support the development of innovative drugs, including optimizing procurement rules and ensuring the stability of clinical drug supplies [1][3][6]. 5. **Future Trends in Pricing**: The rate of price reductions for drugs and consumables is expected to slow down, with domestic alternatives becoming more prevalent as the price drop from centralized procurement decreases [2][11]. Additional Important Content 1. **Challenges Faced by Companies**: Many companies are facing losses due to aggressive price competition, which has led to a reluctance to participate in negotiations for new drug listings in the medical insurance directory [4][6]. 2. **Policy Changes in Procurement**: Future procurement rules may include dynamic adjustment mechanisms and a dual regulation system for reporting quantities, aimed at improving market fairness and encouraging genuine innovation [8][9]. 3. **Monitoring and Compliance Measures**: Enhanced supervision measures are being proposed, including strict checks on production lines and the establishment of a blacklist for companies with violations [10]. 4. **Market Dynamics for Medical Devices**: The competition in the medical device sector is characterized by malicious low-price competition, particularly in imaging equipment and orthopedic implants, but policy adjustments are expected to improve this situation [12][13]. 5. **Potential Inclusion of Anesthetic Drugs in Procurement**: The likelihood of anesthetic drugs being included in centralized procurement is low due to strict regulations and limited competition among manufacturers [17][18]. This summary encapsulates the key points discussed in the conference call, highlighting the current state and future outlook of the pharmaceutical industry in light of recent regulatory changes.

Report Investment Rating The document does not mention the industry investment rating. Core Viewpoints The report provides a comprehensive overview of the overnight market trends, important macro - economic news, and developments in various financial sectors including futures, stocks, bonds, and foreign exchange. It also presents data on different industries such as manufacturing, real estate, and energy, along with policy updates and market expectations. Summary by Category Overnight Market Trends - International precious metal futures generally rose, with COMEX gold futures up 1.28% at $3349.90 per ounce and COMEX silver futures up 0.20% at $36.25 per ounce [2][46] - International oil prices strengthened slightly, with the US oil main contract up 0.65% at $65.53 per barrel and Brent crude main contract up 0.69% at $67.20 per barrel [3][46] - Most London base metals declined, except LME copper which rose 0.75% to $9943.00 per ton [4][46] - Most CBOT agricultural product futures rose, with wheat up 2.14% and soybeans up 0.05%, while corn fell 0.86% [4] - Domestic futures were mixed, with caustic soda up over 2% and rebar up nearly 1%, while sugar, PX, and PTA fell over 1% [4] Macro - economic News - Trump's trade officials are seeking smaller - scale trade deals to avoid tariff re - imposition [6] - The Caixin China Manufacturing PMI in June was 50.4, up 2.1 points from May and back above the critical point [6] - China will promote the construction of a unified national market and address low - price disorderly competition [6] - China's heavy - truck sales in June were about 92,000, up 4% from May and 29% from last year [6] - Trump doubts a trade deal with Japan by July 9 [7] - Fed Chair Powell leaves the door open for July rate - cut decision [7][15][37] Energy and Chemical Futures - Domestic airlines will raise fuel surcharges from July 5 [10] - China raised domestic gasoline and diesel prices on July 1 [10][30] - Some domestic photovoltaic glass manufacturers plan to cut production in July [10] Metal Futures - China's electrolytic copper production in June decreased 0.3% month - on - month but increased 12.93% year - on - year, and is expected to rise in July [12] - HSBC raised its 2026 gold price forecast to $3125 per ounce [13] Black - series Futures - China's 47 - port imported iron ore inventory decreased by 28.74 tons on July 1 compared to the previous Monday [17] - Australian and Brazilian major port iron ore inventory decreased slightly in late June [17] Agricultural Product Futures - China's major oil mills' soybean crushing and bean - meal output are expected to remain high in July, and bean - meal inventory may rise [19] - Malaysia's palm oil production decreased in June [19] - China's national soybean, corn, and palm oil export and production forecasts are updated [22] - ICE raw sugar July contract delivery volume was the lowest since 2014 [23] - US soybean crushing and soybean oil production increased in May [23] Financial Markets Stocks - A - shares showed a mixed trend on Tuesday, with the Shanghai Composite Index up 0.39% [25] - Hong Kong stocks were closed on Tuesday [26] - Northeast Securities' gold - stock portfolio led with a 45.45% return in H1 [27] - IPO acceptance reached a peak in June, with the Beijing Stock Exchange leading [28] - Heyuan Biotech's IPO application was approved on the Science and Technology Innovation Board [28] - Analysts are optimistic about A - shares' medium - to - long - term prospects and the continuation of the Hong Kong IPO boom [29] International Stocks - US stocks closed mixed, with the Dow up 0.91% and the S&P 500 down 0.11% [43] - European stocks also closed mixed, with the German DAX down 0.99% and the UK FTSE 100 up 0.28% [43] - The S&P 500 is expected to rise in July but may weaken in August [45] - Hedge funds made large net purchases of US bank stocks last week [45] Bonds - Local government bond issuance increased by about 57.2% in H1 compared to the same period in 2024 [48] - The domestic bond market was generally positive, with most yields of major interest - rate bonds in the inter - bank market falling [49] - US Treasury yields mostly rose, affected by employment and manufacturing data [49] - Japan's 10 - year government bond auction was relatively strong [50] Foreign Exchange - The on - shore RMB against the US dollar rose on Tuesday [51] - The euro - dollar exchange rate is a concern for policymakers if it breaks above 1.2 [51] - The US dollar index fell 0.13% on Tuesday [53] Industry News - New energy vehicle sales in June showed a mixed performance, with some brands hitting new highs and others declining [32] - China's National Healthcare Security Administration is adjusting the medical insurance drug catalog and supporting innovative drugs [32] - China's film box office and attendance increased in H1 2025 [33] - Real estate investment by top 100 developers increased in H1, and Beijing's second - hand housing transactions rose [33][34] - Shanghai will subsidize the replacement of old electric bicycles [35] International News - Trump is tough on trade negotiations with Japan and the EU [37] - The EU and the US are in the final stage of trade - deal negotiations [37] - Eurozone inflation reached the ECB's target in June, and the ECB may slow down rate - cuts [37][39] - US manufacturing PMI improved but remained in contraction in June [38] - US job openings increased in May [39] - South Korea may tax dividend income separately [41] - Argentina will appeal a court ruling on its national oil company [42]